Last reviewed · How we verify

SODIUM PICOSULFATE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 5/100

SODIUM PICOSULFATE is a Calculi Dissolution Agent [EPC] drug. It is currently FDA-approved (first approved 2012).

Sodium picosulfate is a small molecule stimulant laxative used for bowel preparation before colonoscopy and in the treatment of colorectal cancer, among other conditions. It is often administered in combination with other substances, such as lactulose or polyethylene glycol, as part of bowel cleansing solutions.

At a glance

Generic nameSODIUM PICOSULFATE
Drug classCalculi Dissolution Agent [EPC]
ModalitySmall molecule
PhaseFDA-approved
First approval2012

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SODIUM PICOSULFATE

What is SODIUM PICOSULFATE?

SODIUM PICOSULFATE is a Calculi Dissolution Agent [EPC] drug.

What drug class is SODIUM PICOSULFATE in?

SODIUM PICOSULFATE belongs to the Calculi Dissolution Agent [EPC] class. See all Calculi Dissolution Agent [EPC] drugs at /class/calculi-dissolution-agent-epc.

When was SODIUM PICOSULFATE approved?

SODIUM PICOSULFATE was first approved on 2012.

What development phase is SODIUM PICOSULFATE in?

SODIUM PICOSULFATE is FDA-approved (marketed).

What are the side effects of SODIUM PICOSULFATE?

Common side effects of SODIUM PICOSULFATE include Nausea, Vomiting, Abdominal pain, Watery diarrhea, Abdominal bloating, Abdominal distention. Serious adverse events: Hypoglycemia (abnormally low glucose levels), Electrolyte abnormalities, Rash, Urticaria.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing